Long COVID exhibits clinically distinct phenotypes at 3–6 months post-SARS-CoV-2 infection: results from the P4O2 consortium

Autor: Annemie M W J Schols, Anke H Maitland-van der Zee, Joop P van den Bergh, Sebastiaan Holverda, Esther J Nossent, Els J M Weersink, Marianne A van de Pol, Firdaus A A Mohamed Hoesein, Lisanne T Schuurman, Ivo van der Lee, Jelle M Blankestijn, Mahmoud I Abdel-Aziz, Nadia Baalbaki, Somayeh Bazdar, Inés Beekers, Rosanne J H C G Beijers, Lizan D Bloemsma, Merel E B Cornelissen, Debbie Gach, Laura Houweling, John J L Jacobs, Reneé Jonker, Paulien M A Linders, Lieke C E Noij, Daphne W Schaminee, Brigitte Sondermeijer, J J Miranda Geelhoed, Yolanda de Wit-van Wijck

Publikováno v: BMJ Open Respiratory Research, Vol 11, Iss 1 (2024)

Background Four months after SARS-CoV-2 infection, 22%–50% of COVID-19 patients still experience complaints. Long COVID is a heterogeneous disease and finding subtypes could aid in optimising and developing treatment for the individual patient.Meth

Externí odkaz: https://doaj.org/article/08cab7016402442e9e9b869081c263bd

Pulmonary function 3–6 months after acute COVID-19: A systematic review and multicentre cohort study

Autor: Merel E.B. Cornelissen, Asabi Leliveld, Nadia Baalbaki, Debbie Gach, Ivo van der Lee, Esther J. Nossent, Lizan D. Bloemsma, Anke H. Maitland-van der Zee

Publikováno v: Heliyon, Vol 10, Iss 6, Pp e27964- (2024)

Aims: To describe pulmonary function 3–6 months following acute COVID-19, to evaluate potential predictors of decreased pulmonary function and to review literature for the effect of COVID-19 on pulmonary function. Materials and methods: A systemati

Externí odkaz: https://doaj.org/article/0ae1818b65264791a50c48fb3fe9636a

Pharmacokinetics and pharmacodynamics of imatinib for optimal drug repurposing from cancer to COVID-19

Autor: Nadia Baalbaki, Erik Duijvelaar, Medhat M. Said, Job Schippers, Pierre M. Bet, Jos Twisk, Sarah Fritchley, Cristina Longo, Kazien Mahmoud, Anke H. Maitland-van der Zee, Harm Jan Bogaard, Eleonora L. Swart, Jurjan Aman, Imke H. Bartelink

Publikováno v: Baalbaki, N, Duijvelaar, E, Said, M M, Schippers, J, Bet, P M, Twisk, J, Fritchley, S, Longo, C, Mahmoud, K, Maitland-van der Zee, A H, Bogaard, H J, Swart, E L, Aman, J & Bartelink, I H 2023, ' Pharmacokinetics and pharmacodynamics of imatinib for optimal drug repurposing from cancer to COVID-19 ', European Journal of Pharmaceutical Sciences, vol. 184, 106418 . https://doi.org/10.1016/j.ejps.2023.106418
European Journal of Pharmaceutical Sciences, 184:106418. Elsevier

Introduction: In the randomized double-blind placebo-controlled CounterCOVID study, oral imatinib treatment conferred a positive clinical outcome and a signal for reduced mortality in COVID-19 patients. High concentrations of alpha-1 acid glycoprotei

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8ca77a4480a98326896ab48f4b0e96e
https://research.vumc.nl/en/publications/269bef74-d9b2-46e0-b8b4-50fa6d0d2bc8